Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male/Female Volunteers
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- Drug: Matching placeboDrug: BI 1181181 Healthy youngDrug: BI 1181181 healthy elderly
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT02254161
- Locations
- 🇩🇪
1344.2.1 Boehringer Ingelheim Investigational Site, Berlin, Germany
Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BIBT 986 BS in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 23
- Registration Number
- NCT02254070
Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH
Phase 4
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 31
- Registration Number
- NCT02251184
Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 52
- Registration Number
- NCT02251795
Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: TPV + RTV (low dose)Drug: TPV + RTV (high dose)Drug: ddl
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT02251873
Effects of Steady-state TPV/RTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult Volunteers
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02251171
Pharmacokinetics of Tipranavir Soft Elastic Capsules (SEDDS) and Ritonavir and Their Effects on Cytochrome P-450 (3A4) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: TPV low 2Drug: TPV mediumDrug: TPV high 1Drug: TPV low 1Drug: TPV high 2
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 113
- Registration Number
- NCT02251132
Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02251769
The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy Volunteers
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02251119
Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02251158